BAC and Octapharma announce collaboration expansion for G-CSF Custom Ligand.
M2 EQUITYBITES-17 August 2010-BAC and Octapharma announce collaboration expansion for G-CSF Custom Ligand(C)2010 M2 COMMUNICATIONS http://www.m2.com
BAC BV, a provider of antibody-based affinity purification technology, has entered into a licence agreement with Octapharma, an independent, global provider of human proteins for life-threatening diseases based in Switzerland.
Financial details of the license agreement announced today were not available.
Under the terms of the license, Octapharma can use BAC's G-CSF CaptureSelect custom affinity ligand for the purification of recombinant human granulocyte-colony stimulating factor (G-CSF) from human (HEK293F) cell cultures.
Existing G-CSF products are marketed as Filgrastim (E.coli derived) and Lenograstim (CHO derived).
This license reportedly follows success in an earlier collaboration (the feasibility study programme), in which BAC discovered and developed the anti-G-CSF ligand in close collaboration with Octapharma.
BAC BV was established in 1995 as a Unilever subsidiary (NYSE:UL; UN).
((Comments on this story may be sent to email@example.com))